MOTS-c is studied in vitro through two linked readouts: perturbation of the folate cycle and de novo purine biosynthesis, which is reported to raise the intermediate AICAR, and downstream activation of the energy sensor AMPK, measured by phosphorylation markers and metabolite profiling. This guide lays out how to design those assays for MOTS-c as a research material. For sequence, origin and identifiers, see the MOTS-c quick-reference profile.
What pathway is MOTS-c reported to engage?
In cultured cells, MOTS-c has been reported to inhibit the folate cycle and de novo purine synthesis, leading to accumulation of AICAR, an AMP analog that activates AMPK (Lee et al., Cell Metabolism, 2015). A later report described translocation of MOTS-c to the nucleus under metabolic stress. These are literature findings; each laboratory should confirm them in its own cell system rather than assume them.
How do you design an AMPK and folate-cycle experiment?
| Question | Assay | Readout | Key control |
|---|---|---|---|
| Is AMPK phosphorylated? | Immunoblot | Phospho-AMPK (Thr172) and phospho-ACC (Ser79), each normalized to total protein | AICAR as a positive control; an AMPK inhibitor as a pathway control |
| Do purine intermediates change? | Targeted LC-MS metabolomics | AICAR (ZMP), AMP, ADP and ATP | Matched vehicle; scrambled-sequence peptide |
| Does one-carbon flux shift? | LC-MS isotope tracing with labeled serine | Label incorporation into purine and folate-cycle species | An antifolate reference compound |
| What is the energy status? | ATP luminescence or AMP:ATP ratio | Relative ATP and nucleotide ratios | Glucose-free and glucose-replete conditions |
| Is respiration altered? | Extracellular flux analysis | Oxygen consumption and extracellular acidification rates | Oligomycin, FCCP, rotenone and antimycin A sequence |
| Where does the peptide localize? | Immunofluorescence or subcellular fractionation | Cytosolic versus nuclear signal | Unstressed versus metabolically stressed cells |
What controls does the experiment need?
- Vehicle: the exact solvent and final solvent percentage used for the peptide, in every well.
- Sequence control: a scrambled or reversed 16-residue peptide to separate sequence-specific effects from general peptide effects.
- Pathway controls: AICAR to confirm the cells can activate AMPK, and an AMPK inhibitor to confirm the readout depends on it.
- Time course: phosphorylation markers and metabolite pools move on different timescales, so sample at several time points.
- Medium state: glucose and serum levels change basal AMPK activity, so record and hold them constant.
How should concentrations be set?
Work in molarity and run a concentration series, for example half-log steps across the micromolar range, chosen for your cell system. Convert vial mass to a molar stock with the tables in MOTS-c 10 mg vial: stock concentration math. Because lyophilized powder carries counter-ions and water, use the net peptide content from the certificate of analysis where it is reported.
What are the common pitfalls?
- Endotoxin: contaminating endotoxin can itself trigger stress signaling in cultured cells and confound AMPK readouts, so use material with a reported endotoxin result.
- Peptide stability: peptidases in serum-containing medium can degrade a 16-residue peptide; prepare working solutions fresh and consider short incubations.
- Methionine oxidation: MOTS-c contains two methionine residues that can oxidize in solution, so keep stocks as single-use aliquots.
- Normalization: report phospho-signal relative to total protein, not to a loading control alone.
Related research guides
- Sourcing MOTS-c as a research material: COA and purity
- MOTS-c vs SS-31: two mitochondria-directed peptides
- Measuring mitochondrial function in vitro: key assays
- Mitochondrial metabolism in vitro: methods and readouts
Research-use note
All materials discussed are supplied for in vitro laboratory research use only, and are not for human or animal use.
